ERBB2 and breast cancer: However, a recent study (DESTINY-Breast04) showed that not only BC patients with HER2 overexpression but also patients with a low or moderate HER2 expression could benefit from antibody–drug conjugates like trastuzumab deruxtecan (T-DXd) [12].